OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
MBCOF
MARVEL BIOSCIENCES CORP.
0.1263
0.0037
3.02%
0.1265 / 0.13 (5000 x 5000)
MARVEL BIOSCIENCES CORP.
Suite 420, 505 8th Avenue S.W.
Calgary, AB T2P 1G2
Canada
Suite 420, 505 8th Avenue S.W.
Calgary, ALB T2P 1G2
Canada
Mr. Nijjar is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. This experience has allowed him to help his clients successfully navigate regulatory and financial environments within which they operate. Mr. Nijjar holds a CPA CMA designation from the Chartered Professional Accountants of British Columbia and a BComm from the University of British Columbia.
Dr. Williams earned his Ph.D. at the University of Alberta under the guidance of Dr. Lorne Tyrrell, who discovered Lamivudine, a treatment of Hepatitis B. Dr. Williams is the co-founder of Sanomune, a company focused on neurological and autoimmune disorders. He is also an inventor of multiple patents who has been awarded several research grants. He has overseen the approval of several Phase II clinical trials in therapeutic areas ranging from diabetes, Alzheimer's disease and rheumatoid arthritis.
Dr. Williams earned his Ph.D. at the University of Alberta under the guidance of Dr. Lorne Tyrrell, who discovered Lamivudine, a treatment of Hepatitis B. Dr. Williams is the co-founder of Sanomune, a company focused on neurological and autoimmune disorders. He is also an inventor of multiple patents who has been awarded several research grants. He has overseen the approval of several Phase II clinical trials in therapeutic areas ranging from diabetes, Alzheimer's disease and rheumatoid arthritis.
None
50 Burnhamthorpe Road West,
Suite 900
Mississauga, ON L5B 3C2
Canada
250 2 St SW #1000
Calgary, AB T2P 0C1
Canada
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
NA
